Literature DB >> 33034160

The burden of respiratory syncytial virus infections among children with sickle cell disease.

Christina A Rostad1,2, Alexander N Maillis3, Kristina Lai3, Nitya Bakshi3,4, Robert C Jerris5,6, Peter A Lane3,4, Marianne E Yee3,4, Inci Yildirim1,2,7.   

Abstract

BACKGROUND: Although respiratory syncytial virus (RSV) is the leading cause of pediatric lower respiratory tract infections, the burden of RSV in children with sickle cell disease (SCD) is unknown.
METHODS: We conducted a retrospective, nested, case-control study of children with SCD <18 years who had respiratory viral panels (RVPs) performed at Children's Healthcare of Atlanta from 2012 to 2019. We abstracted the medical records to describe the demographics, clinical features, and outcomes of children who tested positive for RSV (cases) versus children who tested negative (controls). We calculated the annual incidence of RSV and related hospitalization rates with 95% confidence intervals (CIs) and used multivariate logistic regression to evaluate associations.
RESULTS: We identified 3676 RVP tests performed on 2636 patients over seven respiratory seasons resulting in 219/3676 (6.0%) RSV-positive tests among 160/2636 (6.1%) patients. The average annual incidence of laboratory-confirmed RSV infection among children with SCD was 34.3 (95% CI 18.7-49.8) and 3.8 (95% CI 0.5-7.0) cases per 1000 person-years for those <5 years and 5-18 years, respectively. The RSV-related hospitalization rate for children <5 years was 20.7 (95% CI 8.5-32.8) per 1000 person-years. RSV-positive cases were significantly younger than RSV-negative patients (3.8 years vs 7.6 years, P < .001). Of RSV-positive cases, 22 (13.8%) developed acute chest syndrome and nine (5.6%) required intensive care, which was not significantly different from RSV-negative children with SCD.
CONCLUSION: RSV infections are common in children with SCD with higher burden in younger patients. RSV is associated with considerable morbidity, including higher rates of hospitalization compared to the general population.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  acute chest syndrome; respiratory syncytial virus; sickle cell disease

Mesh:

Year:  2020        PMID: 33034160      PMCID: PMC8246443          DOI: 10.1002/pbc.28759

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  24 in total

1.  Guideline on the management of acute chest syndrome in sickle cell disease.

Authors:  Jo Howard; Nicholas Hart; Marilyn Roberts-Harewood; Michelle Cummins; Moji Awogbade; Bernard Davis
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

2.  Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.

Authors:  E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

3.  Atopic disposition, wheezing, and subsequent respiratory syncytial virus hospitalization in Danish children younger than 18 months: a nested case-control study.

Authors:  Lone Graff Stensballe; Kim Kristensen; Eric A F Simoes; Henrik Jensen; Jens Nielsen; Christine Stabell Benn; Peter Aaby
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

4.  Mycoplasma disease and acute chest syndrome in sickle cell disease.

Authors:  Lynne Neumayr; Evelyne Lennette; Dana Kelly; Ann Earles; Stephen Embury; Paula Groncy; Mauro Grossi; Ranjeet Grover; Lillian McMahon; Paul Swerdlow; Peter Waldron; Elliott Vichinsky
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

5.  Asthma and acute chest in sickle-cell disease.

Authors:  Jessica H Boyd; Asif Moinuddin; Robert C Strunk; Michael R DeBaun
Journal:  Pediatr Pulmonol       Date:  2004-09

6.  Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Authors:  Timothy F Feltes; Allison K Cabalka; H Cody Meissner; Franco M Piazza; David A Carlin; Franklin H Top; Edward M Connor; Henry M Sondheimer
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

7.  Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease.

Authors:  Deborah Dean; Lynne Neumayr; Dana M Kelly; Samir K Ballas; Klara Kleman; Shanda Robertson; Rathi V Iyer; Russell E Ware; Mabel Koshy; Wayne R Rackoff; Chuck H Pegelow; Peter Waldron; Lennette Benjamin; Elliott Vichinsky
Journal:  J Pediatr Hematol Oncol       Date:  2003-01       Impact factor: 1.289

8.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

9.  Burden of influenza-related hospitalizations among children with sickle cell disease.

Authors:  David G Bundy; John J Strouse; James F Casella; Marlene R Miller
Journal:  Pediatrics       Date:  2010-01-25       Impact factor: 7.124

Review 10.  Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Authors:  Colleen Wegzyn; Lim Kai Toh; Gerard Notario; Sophie Biguenet; Kristina Unnebrink; Caroline Park; Doris Makari; Michael Norton
Journal:  Infect Dis Ther       Date:  2014-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.